Sponsored

Radiopharm (ASX:RAD) riding high on Orphan Drug Designation for DUNP19 - Kalkine Media

September 12, 2022 10:13 AM AEST | By Aditi Sarkar
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Highlights

  • Radiopharm has secured the Orphan Drug Designation for its DUNP19 technology, studied in osteosarcoma.
  • The development will offer a range of benefits and incentives to RAD including tax benefits and market exclusivity to the drug post approval.
  • DUNP19 is the first-in-class therapy that can overcome a major limitation of currently available antibodies for cancer treatment.
  • Osteosarcoma is a rare bone cancer with surgery and chemotherapy the only currently available treatments.

Radiopharm Theranostics (ASX:RAD) has provided an important update on one of the latest assets added to its portfolio.

The ASX-listed radiopharmaceuticals player has bagged the Orphan Drug Designation for its DUNP19 technology to treat a rare bone cancer known as osteosarcoma.

Radiopharm’s shares closed the day’s trade at AU$0.180 on 09 Sep 2022. The company has a market capitalisation of AU$43.21 million.

What does Orphan Drug Designation mean for RAD

The excellent recognition has been granted by the US Food & Drug Administration (FDA). The FDA grants the Orphan Drug Designation to biological products or drugs with the potential for diagnosis, prevention or treatment of rare diseases and conditions.

The Orphan drug designation provides benefits such as user fee exemptions, tax credits for qualified clinical trials, and a potential seven years of market exclusivity post approval.

RAD-UCLA Licensing agreement for DUNP19

In April this year, Radiopharm signed an exclusive licensing agreement with the University of California Los Angeles (UCLA) Technology Development Group (UCLA-TDG) for the LRRC15 antibody “DUNP19”.

Under the agreement, Radiopharm gained the rights to develop DUNP19 as an Antibody-Drug Conjugates (ADC) within radiotherapy as part of its clinical development pipeline. Its major indication is osteosarcoma.

The First-in-class therapy

Expression of LRRC15 is done by cancer cells and the surrounding tumour microenvironment (TME) cells with very high production in aggressive tumours resistant to treatment. However, it is not produced by healthy normal tissues.

DUNP19 is the first-in-class therapy that can overcome a major limitation of the currently available antibodies for cancer treatment, i.e., they omit TME cells. It is a promising antibody with the dual potential to find and destroy both cancer and TME cells that make up more than 50% of tumour masses. It also has faster internalisation properties.

Osteosarcoma is majorly prevalent in children, young adults, and adolescents. Currently, surgery and chemotherapy are the only available treatments for the disease.

The company believes that osteosarcoma is a perfect candidate for proof-of-concept testing as the aggressive form of this disease has one of the highest expressions of LRRC15.

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.



Top ASX Listed Companies


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.